Understanding RSV ⁢and Why It’s a Threat to Seniors

Respiratory Syncytial Virus (RSV) is ⁣a common respiratory virus that usually causes mild, cold-like symptoms.However, for older adults, particularly those with underlying⁤ health conditions, RSV can be severe. It’s a leading cause of pneumonia, bronchitis, and hospitalization, and can exacerbate existing conditions like chronic obstructive pulmonary disease (COPD) and ⁢congestive heart failure. Prior to the availability of‍ a vaccine, RSV was estimated to cause between 60,000 and 160,000‍ hospitalizations and 6,000 to 10,000⁤ deaths annually among adults 65 years and ⁤older in the United States.

The virus spreads through respiratory droplets produced when an infected person coughs or sneezes. Older adults are more vulnerable due to age-related decline ‍in immune function and increased prevalence of comorbidities.

The Arexvy Vaccine: how it effectively works and Trial Results

arexvy, developed by GSK, is a recombinant subunit vaccine containing a stabilized prefusion F protein. This protein is found on the surface of the RSV virus and is crucial for the virus to enter cells. By presenting this protein to the immune system,the vaccine triggers the production of antibodies that can neutralize the virus and prevent infection.

The Phase 3 PROTECT⁤ trial, involving⁣ nearly⁣ 25,000 adults aged 60 years ⁢and older, demonstrated a vaccine efficacy of 82.6% against RSV-associated LRTI with three or more symptoms. The trial, conducted across multiple countries, showed consistent efficacy across different age groups and underlying health conditions. Specifically, the vaccine demonstrated 94.1% efficacy against severe RSV-associated LRTI and 81.5% efficacy against hospitalization ⁤due to RSV.

Data published in the New England Journal of Medicine on September 11,2025,confirmed these findings. The study meticulously tracked participants for a⁣ median of 9.4 months, revealing a statistically significant reduction in RSV-related illness among those vaccinated compared to the placebo group.

Safety Profile

The vaccine was generally ‍well-tolerated. The most common side effects reported in the trial were local reactions at the injection site,such ‍as pain,redness,and swelling,as well as systemic symptoms like fatigue,muscle pain,and headache.‍ Serious adverse events were rare and not significantly different between the ⁤vaccine⁢ and ‍placebo groups. However, a small increased risk of inflammatory conditions, such as guillain-Barré⁣ syndrome, was ⁤observed, prompting ongoing monitoring by regulatory agencies.

Who Should Get the RSV Vaccine?

The FDA approved Arexvy for adults aged 60 years and older. The Centers for⁤ Disease control and Prevention (CDC) recommends that adults in⁣ this ‍age group may receive an RSV vaccine, based on shared clinical⁢ decision-making with their healthcare provider. This means that individuals should discuss their risk factors, health status, and preferences with their doctor to determine if vaccination is right for them.

Individuals with certain medical conditions, such as heart failure, COPD, diabetes, and chronic kidney disease, are at higher risk‍ of severe RSV illness and may benefit most